COVID-19-Therapeutika und das Antiparasitikum Ivermectin

This procedure is a parliamentary inquiry regarding the use and evaluation of therapeutic treatments for COVID-19, with a specific focus on the antiparasitic drug Ivermectin. It seeks to clarify the official position on the efficacy and safety of these treatments in combating the virus. This affects healthcare providers and patients seeking approved COVID-19 treatments. It focuses on the regulatory assessment of specific medications used in clinical settings.